McArthur, H. L., Rice, S., Chan, I., Leal, J. H. S., Spring, L., Sanchez, K., Bitar, J. S., Unni, N., Syed, S. K., Basho, R. K., Conlin, A. K., Stanton, S., Perlewitz, K., Delgado-Ramos, G. M., Peswani, N., Yuan, Y., CHAN, D., Patil, S., Brufsky, A., Page, D. B. (2026). Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.623